Company news
Silo Pharma, Inc. news in 2021
Silo Pharma, Inc.'s news releases, calls and decks from 2021, newest first.
Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide
December 1, 2021
Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods
November 17, 2021
Silo Pharma Reports Third Quarter Results and Operating Highlights
November 10, 2021
Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease
October 26, 2021
Silo Pharma achieves milestone - Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology
October 6, 2021
Silo Pharma Advances Psychedelic Patent Portfolio
August 24, 2021
Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research
August 10, 2021
Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent
July 26, 2021
Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore
July 11, 2021
Silo Pharma extends agreement for experimental Rheumatoid Arthritis nanoparticle homing peptide
July 6, 2021
Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients
June 7, 2021
Silo Pharma Submits Application for NASDAQ up-listing
May 24, 2021
Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.
May 12, 2021
Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics
April 27, 2021
Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ
April 21, 2021
Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology
April 6, 2021
Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis
March 3, 2021
Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS
February 17, 2021
Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds
February 9, 2021
Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease
January 25, 2021
Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore
January 12, 2021
Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications
January 10, 2021
Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities
January 5, 2021